Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
Journal of Clinical Medicine · 15.02.2023 · 12 (4) · 1524
DOI: 10.3390/jcm12041524 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 15.02.2023. Verfasst von Jieun Lee. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seou…. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT), Research Fund of Seoul St. Mary's Hospital, The Catholic University of Korea, Research Fund of Seoul St. Mary’s Hospital, The Catholic University of Korea.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and is characterized by an aggressive nature and a high rate of recurrence despite neoadjuvant and adjuvant chemotherapy. Although novel agents are constantly being introduced for the treatment of breast cancer, conventional cytotoxic chemotherapy based on anthracyclines and taxanes is the mainstay treatment option for TNBC. Based on CTNeoBC pooled analysis data, the achievement of pathologic CR (pCR) in TNBC is directly linked to improved survival outcomes. Therefore, the treatment paradigm for early TNBC has shifted to neoadjuvant treatment, and the escalation of neoadjuvant chemotherapy to improve the pCR rate and the addition of post-neoadjuvant chemotherapy to control the residual disease have been investigated. In this article, we review the current treatment landscape for early TNBC, from standard cytotoxic chemotherapy to recent data on immune checkpoint inhibitors, capecitabine, and olaparib.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
- Cancer Research Institute, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Förderung
- National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT)
- Research Fund of Seoul St. Mary's Hospital, The Catholic University of Korea
- Research Fund of Seoul St. Mary’s Hospital, The Catholic University of Korea
Zitieren
APA
Lee, J. (2023). Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC). Journal of Clinical Medicine, 12(4), 1524. https://doi.org/10.3390/jcm12041524
Vancouver
Lee J. Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC). Journal of Clinical Medicine. 2023;12(4):1524. doi:10.3390/jcm12041524
BibTeX
@article{Lee2023,
author = {Lee, Jieun},
title = {Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {4},
pages = {1524},
doi = {10.3390/jcm12041524}
}
EUVIMED